Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
comparing different types of cuclophotocoagulation with cataract extraction to cataract extraction and goniocynechiolysis in cases of chronic angle closure glaucoma
Evaluation of the safety of MP-TSCPC , CW-TSCPC and endoscopic cyclophotocoagulation when combined with phacoemulsification in cases with CACG Comparing the efficacy of the combined procedures in control of the IOP and the success rate versus lens extraction combined with synechiolysis
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A:phaco+MP-TSCPC | Experimental | 22 patients with primary angle closure glaucoma will undergo phacoemulsification and micropulse cyclophotocoagulation |
|
| B:phaco+TSCPC | Experimental | 22 patients with primary angle closure glaucoma will undergo phaco and transscleral cyclophotocoagulation |
|
| C:phaco+endocyclophotocoagulation | Experimental | 22 patients with primary angle closure glaucoma will undergo phaco and endocyclophotocoagulation after cataract removal |
|
| D:phaco GSL | Experimental | 22 patients with primary angle closure glaucoma will undergo phaco and goniosynechiolysis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| phaco+MP-TSCPC | Procedure | The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation. |
| Measure | Description | Time Frame |
|---|---|---|
| the percentage of intraocular pressure change | measuring the intraocular pressure after 1M, 3M and 6M | 6 Months |
| Measure | Description | Time Frame |
|---|---|---|
| percent change of antiglaucoma medications | the number of medication before and after the procedure | 6 Months |
Not provided
Inclusion Criteria:
chronic angle closure glaucoma
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ahmed Abdelrahman, PhD | kasr alainy | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kasr Alainy | Cairo | 11562 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015812 | Glaucoma, Angle-Closure |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D009798 | Ocular Hypertension |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| phaco+TSCPC | Procedure | The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation. |
|
| phaco+endocyclophotocoagulation | Procedure | phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction |
|
| phaco GSL | Procedure | phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic. |
|